Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21604667 | 1.00 | EED (0.44) | EEDHRH4HRH3KCNH2ACP1 | |
| SCHEMBL21604573 | 0.85 | EED (0.54) | EEDHRH4HRH3KCNH2ACP1 | |
| SCHEMBL21604575 | 0.85 | EED (0.54) | EEDHRH4HRH3KCNH2ACP1 | |
| SCHEMBL20281478 | 0.83 | EED (0.52) | EEDHRH4HRH3KCNH2BRD4 | |
| SCHEMBL21359121 | 0.83 | EED (0.52) | EEDHRH4HRH3KCNH2BRD4 | |
| SCHEMBL21604650 | 0.81 | EED (0.44) | EEDHRH4HRH3KCNH2CHEK1 | |
| SCHEMBL21604661 | 0.81 | EED (0.44) | EEDHRH4HRH3KCNH2CHEK1 | |
| SCHEMBL21603160 | 0.77 | EED (0.44) | EEDHRH4HRH3 | |
| SCHEMBL21603154 | 0.77 | EED (0.44) | EEDHRH4HRH3 | |
| SCHEMBL20281657 | 0.77 | EED (0.44) | EEDHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | EED 4588/4885HRH4 4152/4885HRH3 3480/4885 |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | EED 4588/4885HRH4 4152/4885HRH3 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.